Belgium· BE-AMP-SAM204732-00

Ziagen 20 mg/ml

A abacavir product containing abacavir, registered in Belgium by ViiV Healthcare. The same ATC class is registered in 16 of our 19 countries.

ATC J05AF06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedZiagen 20 mg/mlATCJ05AF06REGISTER NO.BE-AMP-SAM204732-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Abacavir is registered in 16 of 19 countries.

Countries holding a registration under ATC J05AF06 (abacavir), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose

Abacavir · ATC J05AF06

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of abacavir costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), the median price runs from $3.98 in France to $9.36 in Switzerland — a ×2.3 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Abacavir · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$9.36
  • FR France$3.98
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Abacavir
Manufacturer
ViiV Healthcare
Country
Belgium (BE)
ATC code
J05AF06
ATC class
Abacavir
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    1487529
  • be_apb
    0767996

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

131 interactions on record for abacavir.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Abacavir · interactions on record

131 records

  • 4 severe
  • 23 moderate
  • 6 minor
  • 96 info

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • LeflunomideL04AK01severe
  • TeriflunomideL04AK02severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Abacavir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All abacavir products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Spain · Abacavir Tarbis
  • Finland · Abacavir Accord
  • France · Abacavir Arrow, Abacavir Sandoz
  • United Kingdom (Northern Ireland) · Abacavir Milpharm, Abacavir Mylan
  • Iceland · Ziagen
  • Italy · Abacavir Mylan
  • Liechtenstein · Ziagen
  • Netherlands · Abacavir Accord, Abacavir Sandoz
  • Norway · Ziagen
  • Portugal · Abacavir Farmoz, Abacavir Generis
  • Romania · Abacavir Aurobindo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/52a98750-0cb6-4ebd-aae1-9b4b268ef60f
GET /v1/drugs/52a98750-0cb6-4ebd-aae1-9b4b268ef60f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oral solution",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ziagen 20 mg/ml",
  "name_fr": "Ziagen 20 mg/ml",
  "name_nl": "Ziagen 20 mg/ml",
  "amp_code": "SAM204732-00",
  "strengths": [
    "20.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Abacavir",
    "Methyl Parahydroxybenzoate",
    "Propylene Glycol",
    "Saccharin Sodium",
    "Sodium Hydroxide",
    "Sorbitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Abacavir",
  "authorisation_numbers": [
    "EU/1/99/112/002"
  ]
}

See everything about abacavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.